A special advisory panel recently concluded that the drug Avastin, the world's best selling cancer drug, is useless for breast cancer. This panel has now recommended that the Food and Drug Administration revoke its approval for this indication. This expensive drug has been a go-to drug for breast cancer patients for the past few years.
Unfortunately, studies now show that there has been no benefit, only false hope. This announcement may inevitably lead to an increase in product liability or medical malpractice lawsuits. Attorneys practicing in this area of law should educate themselves according.
To read the full NY Times article, CLICK HERE.
